

Datasheet: MCA6091 BATCH NUMBER 153012

Description:	HUMAN ANTI CD20 (RITUXIMAB BIOSIMILAR)		
Specificity:	CD20		
Format:	Purified		
Product Type:	Monoclonal Antibody		
Clone:	10F381		
Isotype:	lgG1		
Quantity:	0.2 mg		

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA				

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human		
Product Form	Human IgG1 (kappa) antibody - liquid		
Preparation	Purified recombinant IgG prepared by affinity chromatography on Protein A from a mammalian cell line		
Buffer Solution	Phosphate buffered saline		
Preservative Stabilisers	0.02% Proclin 300		
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml		
Immunogen	Human lymphoblastoid cell line SB		
Specificity	Human Anti-CD20 antibody, clone 10F381 is a research grade biosimilar of the		

monoclonal antibody drug rituximab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic rituximab antibody clone 10F381.

This antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-rituximab antibodies, for example <u>HCA186</u> and <u>HCA201</u>. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-rituximab antibody in IgG1 format as a reference standard, for example <u>HCA201</u>.

Rituximab is a chimeric monoclonal antibody with murine variable region and human constant domains. It targets CD20, a protein found on the surface of B cells. Binding of the drug to its target triggers cell death through a number of mechanisms, including apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved for the treatment of B cell malignancies, transplant rejection and autoimmune disorders.

This product is NOT FOR THERAPEUTIC USE.

View a summary of supporting anti-rituximab antibody products.

Purity	>98% by SDS PAGE
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Health And Safety Information	Material Safety Datasheet documentation #20463 available at: https://www.bio-rad-antibodies.com/SDS/MCA6091 20463
Licensed Use	For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Regulatory	For research purposes only

Related Products

Recommended Useful Reagents

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK001P)

HISPEC ASSAY DILUENT (BUF049A)

HUMAN ANTI RITUXIMAB (HCA061)

HUMAN ANTI RITUXIMAB (HCA062)

HUMAN ANTI RITUXIMAB (HCA186)

HUMAN ANTI RITUXIMAB (HCA201)

RAT ANTI RITUXIMAB:FITC (MCA2260F)
RAT ANTI RITUXIMAB:HRP (MCA2260P)
RAT ANTI RITUXIMAB (MCA2260)

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M373148:200827'

Printed on 01 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint